Basic Information
Starna Therapeutics (Suzhou) Co., Ltd. was founded in August 2021 with the mission of "serving life and health." It is committed to developing innovative drugs centered on RNA to address unmet clinical needs. Its R&D pipeline covers areas such as infectious disease vaccines, cancer immunotherapy, and metabolic diseases. The company has assembled a professional team. The core team and scientific advisors originate from the University of Texas Southwestern Medical Center. The founding team has extensive R&D and management experience, having held leadership positions in large pharmaceutical companies and innovative firms, with years of experience in nucleic acid drug development. The scientific advisory team holds positions at top universities both in China and abroad, with several advisors coming from Nobel Prize-winning laboratories. Starna Therapeutics has established an R&D base in Suzhou's Biomedical Industry Park, completed the construction of multiple core platforms, and is gradually forming an independent intellectual property R&D system. It is expected to advance multiple projects into clinical stages within the next three years.